Cancer Pain - Market Insight, Epidemiology And Market Forecast - 2032

DelveInsight's 'Cancer Pain - Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of Cancer Pain historical and forecasted epidemiology as well as the Cancer Pain market trends in the United States, EU4 (Germany, France, Italy and Spain), the UK, and Japan.

The Cancer Pain market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Cancer Pain market size. The report also covers Cancer Pain procedure, SWOT analysis, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, Spain) and the UK
• Japan

Study Period: 2019-2032

Cancer Pain Understanding

Cancer Pain Overview

The International Association for the study of pain defines pain as "an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage." Worldwide, many people are affected by cancer, and the prevalence is rising. Pain is the most typical symptom of cancer at diagnosis and rises in prevalence throughout and beyond cancer treatment and continues to be a major source of suffering in advanced cancer with adverse effects on patients' life quality and caregiver distress. Cancer pain is a complex biologic phenomenon that is poorly understood or classified. No specific and widely acceptable taxonomy of cancer pain exists. In any given patient, different mechanisms can be responsible for the pain. Recently, new perspectives on the biology of pain caused by tumor invasion have emerged.

Continued in the report…

Etiology and Types of Cancer Pain

Generally, in cancer, the pain is caused by the primary tumor, metastatic disease, or cancer-related treatments; however, a primary cause of the pain cannot always be identified. Most cancer pain is caused by the tumor pressing on bones, nerves, or other organs in the body. Classifications based on the pain duration are acute pain, chronic pain, breakthrough pain, and refractory pain.

Acute pain is due to damage caused by an injury and usually lasts <3-6 months. For example, having an operation can cause acute pain. The pain goes when the wound heals; in the meantime, painkillers will usually keep it under control.

Chronic pain lasts >3-6 months and is persistent due to nerve changes. Nerve changes may be due to cancer pressing on nerves or chemicals produced by a tumor. Nerve changes due to cancer treatment can also cause it. Chronic pain continues long after the injury or treatment is over, can range from mild to severe, and can always be there. Sometimes pain can come on quickly, for example, when changing a dressing or moving around; this type is incident pain.

Continued in the report…..

Cancer Pain Epidemiology

The epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Cases of Cancer Pain, Etiology-specific Cases of Cancer Pain, Incident Cases of Chemotherapy-Induced Peripheral Neuropathy, Severity-specific Cases of Cancer Pain, Pathophysiology-specific Cases of Cancer Pain, Temporal Variation-specific Cases of Cancer Pain, Incident Cases of Breakthrough Cancer Pain (BTcP) covering the United States, the EU4 (Germany, France, Italy, Spain), UK and Japan from 2019 to 2032.

Key Findings

• In 2021, the total incident cases of cancer pain in the US were ~2,321,000 cases, which are anticipated to increase in 2032.
• EU4 and the UK, in 2021, accounted for ~2,278,000 cases of cancer pain, which are anticipated to increase by the year 2032.
• Among the EU4 countries, the highest number of cases of cancer pain were found in Germany, i.e., ~634,000 cases in the year 2021, which are estimated to increase by the year 2032.
• In 2021, the incident cases of breakthrough cancer pain were ~379,000 in France. These cases are expected to increase during the forecast period.

Cancer Pain Drug Chapters

Cancer Pain Emerging Drugs

Tetrodotoxin: Wex Pharma

Tetrodotoxin (TTX) is a highly selective sodium channel blocker derived from puffer fish. Sodium channels are found on nerves and are involved in the transmission of nerve impulses. The mechanism of action is primarily due to the blockage of one subclass of sodium channels, NaV 1.7, found predominantly on nociceptive neurons in the periphery. There are changes to this subset of sodium channels in chronic pain conditions. Tetrodotoxin is extremely potent, and much lower dosages are needed to produce an analgesic effect than other drugs.

Product details in the report…

Resiniferatoxin: Sorrento Therapeutics

RTX (resiniferatoxin) is a unique neural intervention molecule that is highly selective and may be applied peripherally (e.g., nerve block, intra-articular) or centrally (e.g., epidural) to control chronic pain across multiple conditions, including arthritis and cancer.

RTX can potentially be a first-in-class drug addressing currently intractable pain in a novel and unique way, targeting the nerves responsible for the chronic debilitating pain signal transmission. RTX strongly binds to TRPV1 receptors and forces open calcium channels located in the end-terminal of the nerve or the soma of the neuron (depending upon the route of administration). This generates a slow and sustained cation influx that rapidly leads to the deletion of TRPV1-positive cells. RTX directly interacts with afferent nerve cells without affecting sensations such as touch, pressure, acute prickling pain, vibration sense, or muscle coordination function.

Products detail in the report…

QIXLEEF: Tetra Bio-Pharma

QIXLEEF is the company's proprietary investigational new drug currently being studied in two FDA-authorized clinical trials. QIXLEEF is a botanical therapy with a fixed dosage of THC and CBD. The drug is inhaled using a medical vaporizer and manufactured in Canada in a licensed cGMP facility authorized by the Canadian Health Authority.

Product details in the report….

Cancer Pain Market Outlook

Cancer subsumes many diseases, varied illness trajectories, and a rapidly changing therapeutic landscape. The burden of cancer-related illness is high for both patients and families, and symptom distress contributes substantially to this burden. Chronic pain is among the most important symptoms in terms of prevalence and potential consequences. Integrating best practices for pain management into humane, effective, and affordable cancer care is a key challenge for healthcare systems worldwide.

Pain is common in cancer patients, particularly in the advanced stage of the disease, when the prevalence is estimated to be >70%, contributing to poor physical and emotional well-being. Increased survival with either life-prolonging or curative treatment results in increased numbers of patients experiencing persistent pain due to treatment, disease, or a combination of both. Approximately 5%-10% of cancer survivors have chronic severe pain that interferes significantly with functioning.

Treatment of chronic cancer-related pain should be individualized, providing balanced benefits and burdens with the broader goals of care. The feasibility, appropriateness, and potential effects of primary disease-modifying treatment must be considered in developing a strategy for pain. If pain is focal and related to mass effect or local destruction by a tumor, radiotherapy can be highly effective, particularly in bone lesions. Whether or not primary disease-modifying therapy is possible, many patients with pain due to active disease need symptomatic treatments.

A comprehensive pain assessment is required to formulate a multimodal management plan that can be implemented. The first step in managing pain is setting appropriate expectations for patients. The etiology of pain influences the expected outcome and improvement in pain intensity and functional status. Several acceptable treatment options can be offered to patients. These include over-the-counter analgesics, non-opioid prescription medications, interventions, complementary therapies, and systemic opioids.

Continued in the report…..

Key Findings

• In 2021, the US has the largest cancer pain market size of ~USD 1,600 million among the 7MM countries.
• Among the EU4 countries, Germany had the highest market size for cancer pain in 2021, i.e., ~USD 200 million.
• The lowest market size among EU4 countries was estimated in Spain with ~USD 90 million in 2021.
• The market size of cancer pain in UK was observed to be ~USD 150 million in 2021.

The United States Market Outlook

This section provides the total cancer pain market size and market size by therapies in the United States.

EU4 and the UK Market Outlook

The total cancer pain market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook

The total cancer pain market size and market size by therapies in Japan are provided.

Cancer Pain Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the cancer pain market or expected to get launched in the market during the study period 2019-2032. The analysis covers the cancer pain market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, and reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Cancer Pain Development Activities

The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers detailed information on collaborations, acquisitions, merger, licensing, and patent details for cancer pain emerging therapies.

Reimbursement Scenario in Cancer Pain

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

Competitive Intelligence Analysis

We perform competitive market Intelligence analysis of the cancer pain market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

• The report covers a descriptive overview of cancer pain, explaining its procedure, types, indications, and currently available therapies.
• Comprehensive insight has been provided into cancer pain epidemiology and treatment.
• Additionally, an all-inclusive account of both the current and emerging therapies for cancer pain is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
• A detailed review of the cancer pain market; historical and forecasted is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM cancer pain market.

Report Highlights:

• The robust pipeline with novel MOA and oral ROA, increasing prevalence, and effectiveness of drugs will positively drive the cancer pain market.
• The companies and academics are working to assess challenges and seek opportunities that could influence cancer pain R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition using cancer pain.
• Major players are involved in developing therapies for cancer pain. The launch of emerging therapies will significantly impact the cancer pain market.
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Cancer pain Report Insights

• Patient Population
• Therapeutic Approaches
• Cancer Pain Pipeline Analysis
• Cancer Pain Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Cancer pain Report Key Strengths

• 11-Year Forecast
• The US, EU4, the UK, and Japan Coverage
• Cancer Pain Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Cancer pain Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• SWOT analysis

Key Questions

Market Insights:

• What was the Cancer Pain market share (%) distribution in 2019 and how it would look like in 2032?
• What would be the Cancer Pain total market size as well as market size by therapies across the 7MM during the forecast period (2022-2032)?
• What are the key findings pertaining to the market across the 7MM Coverage and which country will have the largest Cancer Pain market size during the forecast period (2022-2032)?
• At what CAGR, the Cancer Pain market is expected to grow at the 7MM Coverage level during the forecast period (2022-2032)?
• What would be the Cancer Pain market outlook across the 7MM Coverage during the forecast period (2022-2032)?
• What would be the Cancer Pain market growth till 2032 and what will be the resultant market size in the year 2032?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What are the risk, burdens, and unmet needs of Cancer Pain?
• What is the historical Cancer Pain patient pool in the United States, EU4 (Germany, France, Italy, Spain), the UK and Japan?
• What would be the forecasted patient pool of Cancer Pain at the 7MM Coverage level?
• What will be the growth opportunities across the 7MM Coverage with respect to the patient population pertaining to Cancer Pain?
• Out of the above-mentioned countries, which country would have the highest cases of Cancer Pain during the forecast period (2022-2032)?
• At what CAGR are these cases expected to grow across the 7MM Coverage during the forecast period (2022-2032)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

• What are the current treatment practices in Cancer Pain along with the approved therapy?
• What are the current treatment guidelines for Cancer Pain?
• What are the Cancer Pain marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
• How many companies are developing therapies for Cancer Pain?
• How many emerging therapies are in the mid-stage and late stages of development for Cancer Pain?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Cancer Pain therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Cancer Pain and their status?
• What are the key designations that have been granted for the emerging therapies for Cancer Pain?
• What are the 7MM Coverage historical and forecasted market of Cancer Pain?

Reasons to buy:

• The report will help in developing business strategies by understanding trends shaping and driving Cancer Pain.
• To understand the future market competition in the Cancer Pain market and an insightful review of the market.
• Organize sales and marketing efforts by identifying the best opportunities for Cancer Pain in the 7MM Coverage.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Organize sales and marketing efforts by identifying the best opportunities for the Cancer Pain market.
• To understand the future market competition in the Cancer Pain market.